BP-012

BP-012 is a pediatric reformulation of an existing cholesterol-lowering medication, developed by Brillian Pharma using its proprietary Unidose delivery technology. The product is designed as an oral solution or a lyophilized powder for reconstitution, specifically tailored to meet the needs of pediatric patients who may have difficulty swallowing traditional solid dosage forms. By providing a precise, single-dose format, BP-012 aims to improve compliance and dosing accuracy in the treatment of lipid disorders in children. While the specific active pharmaceutical ingredient has not been disclosed, the drug belongs to the lipid-lowering therapy class, which typically includes agents that inhibit cholesterol synthesis or absorption.